- Home
- GLPG vs BMEZ Comparison
GLPG vs BMEZ Comparison
Compare GLPG & BMEZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GLPG | BMEZ |
|---|---|---|
| Founded | 1999 | N/A |
| Country | Belgium | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 936.9M |
| IPO Year | 2005 | N/A |
Fundamental Metrics
Financial Performance| Metric | GLPG | BMEZ |
|---|---|---|
| Price | $33.04 | $15.58 |
| Analyst Decision | Hold | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $31.33 | N/A |
| AVG Volume (30 Days) | 99.8K | ★ 391.3K |
| Earning Date | 02-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.71% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.54 |
| Revenue | ★ $336,643,201.00 | N/A |
| Revenue This Year | $1.76 | N/A |
| Revenue Next Year | $0.49 | N/A |
| P/E Ratio | ★ N/A | $30.17 |
| Revenue Growth | ★ 10.31 | N/A |
| 52 Week Low | $22.36 | $12.93 |
| 52 Week High | $37.78 | $16.95 |
Technical Indicators
Market Signals| Indicator | GLPG | BMEZ |
|---|---|---|
| Relative Strength Index (RSI) | 59.23 | 63.99 |
| Support Level | $31.71 | $14.80 |
| Resistance Level | $33.91 | $15.22 |
| Average True Range (ATR) | 0.74 | 0.22 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 69.44 | 90.70 |
Price Performance
Historical ComparisonAbout GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About BMEZ BlackRock Health Sciences Term Trust of Beneficial Interest
BlackRock Health Sciences Trust II is a closed-ended management investment company. The investment objective is to provide total return through a combination of current income and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of energy and natural resources companies and equity derivatives with exposure to the energy and natural resources industry.